Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.kopran.com | |
Market Cap | 1,048.34 Cr. | |
Enterprise Value(EV) | 1,126.19 Cr. | 2021-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 12.15 | Trailing Twelve Months Ending 2021-12 |
Price-Earning Ratio (PE) | 17.91 | Trailing Twelve Months Ending 2021-12 |
Industry PE | 28.07 | Trailing Twelve Months Ending 2021-12 |
Book Value / Share | 84.78 | Trailing Twelve Months Ending 2021-12 |
Price to Book Value | 2.57 | Calculated using Price: 217.55 |
Dividend Yield | 0.69 | Period Ending 2021-03 |
No. of Shares Subscribed | 4.82 Cr. | 48,210,605 Shares |
FaceValue | 10 | |
Company Profile | ||
The company was incorporated on April 26, 1958 as a private limited company under the name Kopran Chemical Company Pvt. Ltd. by Ramanlal V Shah Sevantilal, A Shah , Chimanlal G Sheth and Jivanalal M Shah. In 1972, the company’s management was acquired by Chemo Pharma Laboratories Ltd and the Company’s products were marketed by them. Promoted by the Parijat Enterprises, Kopran is currently an integrated health care company. Kopran has used research-based technology to contribute towards total health-care. The company started modestly as a Semi Synthetic Penicillin (SSP) player and expanded to becomes the largest SSP Player in India with an annual SSP facility of over 1200 tones per annum.Subsequently the SSP business was hived off into a separate Company in a joint venture with Synpac Pharmaceuticals Ltd, UK.Kopran Laboratories Ltd. markets and supports high-tech life-saving medical equipments and diagnostics reagents since 1988. Kopran Research Laboratories Ltd. (KRLL) is an emerging research organisation with particular interests in the areas of drug discovery, polymer technology and synthesis of new molecules. Kopran is working towards creating and maintaining a global presence.Presence in Africa through Kampala Pharmaceutical Industries (KPI),a pharmaceutical company engaged in the manufacture and marketing of finished dosage forms in Uganda. The company is having presence in the Middle East Market through a joint venture with Dubai Investment Corporation a leading investment company in Dubai for the manufacture and marketing of finished dosage forms in Dubai. KRLL is a 100% subsidiary of Kopran Ltd. KRLL is recognised by the Department of Science and Industrial Research (DSIR), Government of India. The company is staffed with competent and dedicated team of scientists. Product range of the company includes: Finished Dosage Forms
Active Pharmaceutical Ingredients
Achievements/ recognition:
Future plans:
|
1 Day |
|
-4.21% |
1 Week |
|
-4.98% |
1 Month |
|
-19.26% |
3 Month |
|
-21.72% |
6 Month |
|
-15.76% |
1 Year |
|
+10.15% |
2 Year |
|
+686.80% |
5 Year |
|
+155.79% |
10 Year |
|
+1421.33% |
9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 13.39 | 17.65 | -43.06 | 12.19 | 17.71 | 15.21 | 15.34 | 11.74 | 28.34 | |
Return on Capital Employed (%) | 11.81 | 14.27 | -12.48 | 13.09 | 19.24 | 13.88 | 16.30 | 13.69 | 30.40 | |
Return on Assets (%) | 4.33 | 6.11 | -13.63 | 3.98 | 7.15 | 6.77 | 7.27 | 5.84 | 15.22 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-09* Rs. Cr. |
Shh. Funds | 97 | 115 | 99 | 109 | 125 | 145 | 168 | 190 | 245 | 262 | |
Non Curr. Liab. | 73 | 67 | 18 | 33 | 32 | 31 | 46 | 40 | 34 | 34 | |
Curr. Liab. | 93 | 117 | 158 | 122 | 136 | 136 | 135 | 140 | 161 | 193 | |
Minority Int. | |||||||||||
Equity & Liab. | 263 | 299 | 275 | 264 | 293 | 312 | 349 | 370 | 439 | 489 | |
Non Curr. Assets | 141 | 139 | 105 | 110 | 114 | 118 | 142 | 148 | 162 | 175 | |
Curr. Assets | 123 | 160 | 170 | 154 | 180 | 194 | 208 | 223 | 277 | 314 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 263 | 299 | 275 | 264 | 293 | 312 | 349 | 370 | 439 | 489 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2021-12 Rs. Cr. TTM |
Net Sales | 250 | 303 | 326 | 296 | 310 | 313 | 358 | 360 | 492 | 475 | |
Other Income | 2 | 2 | 7 | 2 | 11 | 11 | 4 | 1 | 18 | 14 | |
Total Income | 252 | 305 | 332 | 299 | 320 | 324 | 362 | 360 | 510 | 489 | |
Total Expenditure | -217 | -260 | -294 | -266 | -274 | -284 | -312 | -313 | -410 | -395 | |
PBIDT | 35 | 45 | 38 | 33 | 47 | 40 | 49 | 47 | 100 | 94 | |
Interest | -12 | -14 | -13 | -13 | -14 | -9 | -9 | -9 | -6 | -5 | |
Depreciation | -12 | -13 | -10 | -8 | -8 | -9 | -9 | -10 | -10 | -11 | |
Taxation | -5 | -2 | -8 | -7 | -22 | -19 | |||||
Exceptional Items | -54 | -1 | -1 | ||||||||
PAT | 11 | 17 | -39 | 11 | 20 | 20 | 24 | 21 | 62 | 59 | |
Minority Interest | |||||||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 11 | 17 | -39 | 11 | 20 | 20 | 24 | 21 | 62 | 59 | |
Adjusted EPS | 3 | 4 | -10 | 2 | 5 | 5 | 6 | 5 | 14 | 14 |
Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 35 | 15 | 3 | 46 | 29 | 16 | 26 | 25 | 31 | 60 | |
Cash Fr. Inv. | -10 | -9 | -9 | -10 | -9 | -18 | -11 | -25 | -13 | -24 | |
Cash Fr. Finan. | -19 | -12 | 7 | -37 | -19 | 2 | -15 | -1 | -18 | -35 | |
Net Change | 6 | -7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
Cash & Cash Eqvt | 7 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 2 |
Fri, 20 May 2022
Announcement under Regulation 30 (LODR)-Credit Rating Credit Rating-Reaffirmed. |
Fri, 13 May 2022
Board Meeting Intimation for Board Meeting For Approval Of Financial Results For The Year Ended 31St March 2022. KOPRAN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2022 inter alia to consider and approve Standalone and Consolidated Audited Financial Result of the Company for the Quarter and Financial Year ended March 31 2022 & recommend Dividend (if any) |
Fri, 13 May 2022
Board to consider Dividend Kopran Ltd has informed BSE that the Meeting of the Board of Directors of the Company is scheduled to be held on May 27 2022 to inter alia consider and approve and take on record the following: 1. Standalone and Consolidated Audited Financial Result of the Company for the Quarter and Financial Year ended March 31 2022. 2. Recommend Dividend (if any) Further pursuant to the Companys Code of Conduct for Regulating & Reporting of Trading by Insiders and for Fair Disclosure the Trading Window for dealing in the securities of the Company which was closed from April 01 2022 will re-open 48 hours after the declaration of the financial results. |
Wed, 25 May 2022 |
|
|
|
|
|